Corcept Therapeutics (CORT) Misses Q1 EPS by 9c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.91 -2.25%
EPS Growth %: -96.6%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -96.6%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of ($0.06), $0.09 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $27.6 million versus the consensus estimate of $25.53 million.
GUIDANCE:
Corcept Therapeutics sees FY2017 revenue of $125-135 million, versus the consensus of $124 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
- JPMorgan Upgrades SHIFT UP Corp (462870:KS) to Overweight
- John Wiley & Sons, Inc. (WLY) Tops Q4 EPS by 12c; offers outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
